Acorda Therapeutics, Inc.
ACOR
Rankning i aktier
#39162
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Aktiekurs
$0.879
Senast synkroniserad: 2024-05-07
Marknadsvärde
$582.38K
Förändring (1 dag)
9.88%
Förändring (1 år)
8,690.00%
Land
US
Handel Acorda Therapeutics, Inc. (ACOR)
Kategori
Healthcare
Antal utestående aktier för Acorda Therapeutics, Inc. (ACOR)
Antal utestående aktier per March 2024: 1.24M
Enligt de senaste finansiella rapporterna och aktiekursen för Acorda Therapeutics, Inc. är det aktuella antalet utestående aktier 1.24M. I slutet av December 2022 hade företaget 985.35K utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Acorda Therapeutics, Inc. (ACOR) från 2016 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 1.24M | 0.00% |
| 2023 | 1.24M | 26.05% |
| 2022 | 985.35K | 85.55% |
| 2021 | 531.05K | 31.38% |
| 2020 | 404.20K | 2.09% |
| 2019 | 395.93K | 1.07% |
| 2018 | 391.75K | 2.20% |
| 2017 | 383.32K | 1.63% |
| 2016 | 377.16K | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 193,083.17% |
IN
|
